دورية أكاديمية
Pre-phase strategy to mitigate first cycle effect in diffuse large B cell lymphoma.
| العنوان: | Pre-phase strategy to mitigate first cycle effect in diffuse large B cell lymphoma. |
|---|---|
| المؤلفون: | Rudresha AH; Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Dr. M H Marigowda Rd., Hombegowda Nagar, Bengaluru, Karnataka, 560029, India., Hassan SA; Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Dr. M H Marigowda Rd., Hombegowda Nagar, Bengaluru, Karnataka, 560029, India., Sreevalli A; Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Dr. M H Marigowda Rd., Hombegowda Nagar, Bengaluru, Karnataka, 560029, India., Lokanatha D; Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Dr. M H Marigowda Rd., Hombegowda Nagar, Bengaluru, Karnataka, 560029, India., Babu MCS; Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Dr. M H Marigowda Rd., Hombegowda Nagar, Bengaluru, Karnataka, 560029, India., Lokesh KN; Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Dr. M H Marigowda Rd., Hombegowda Nagar, Bengaluru, Karnataka, 560029, India., Rajeev LK; Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Dr. M H Marigowda Rd., Hombegowda Nagar, Bengaluru, Karnataka, 560029, India., Saldanha S; Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Dr. M H Marigowda Rd., Hombegowda Nagar, Bengaluru, Karnataka, 560029, India., Thottian AGF; Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Dr. M H Marigowda Rd., Hombegowda Nagar, Bengaluru, Karnataka, 560029, India., Sharma K; Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Dr. M H Marigowda Rd., Hombegowda Nagar, Bengaluru, Karnataka, 560029, India., Jacob LA; Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Dr. M H Marigowda Rd., Hombegowda Nagar, Bengaluru, Karnataka, 560029, India. kmiolinu@gmail.com. |
| المصدر: | Journal of the Egyptian National Cancer Institute [J Egypt Natl Canc Inst] 2022 May 09; Vol. 34 (1), pp. 20. Date of Electronic Publication: 2022 May 09. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: SpringerOpen Country of Publication: England NLM ID: 9424566 Publication Model: Electronic Cited Medium: Internet ISSN: 2589-0409 (Electronic) Linking ISSN: 11100362 NLM ISO Abbreviation: J Egypt Natl Canc Inst Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2019- : London : SpringerOpen Original Publication: Cairo, Egypt : National Cancer Institute |
| مواضيع طبية MeSH: | Antineoplastic Combined Chemotherapy Protocols*/adverse effects , Lymphoma, Large B-Cell, Diffuse*/drug therapy, Adolescent ; Cyclophosphamide/adverse effects ; Doxorubicin/therapeutic use ; Humans ; Prednisone/adverse effects ; Prospective Studies ; Rituximab/adverse effects ; Vincristine/adverse effects |
| مستخلص: | Context: Treatment-related toxicities in DLBCL (diffuse large B cell lymphoma) patients are higher in the initial phase of treatment (first cycle effect). Implementation of pre-phase treatment before definitive chemotherapy had been shown to alleviate some of these side-effects in a non-randomized study conducted earlier in our institute (Lakshmaiah et. al., Eur J Haematol 100:644-8, 2018). Aims: This study was aimed at validating the role of pre-phase treatment in newly diagnosed DLBCL patients. Settings and Design: All newly diagnosed patients with DLBCL above the age of 18 years were evaluated for eligibility and prospectively enrolled. A single-arm prospective study was conducted at the Department of Medical Oncology, in our institute from July 2015 to December 2019. Methods and Material: Patients received vincristine and prednisolone as pre-phase treatment for 7 days after which definitive chemotherapy was instituted on day 1. They were followed up for 30 days post-first cycle chemotherapy. Statistical Analysis Used: Paired Student's t tests and Wilcoxon signed-ranks test were used for comparison of various clinical variables as appropriate. P value of less than 0.05 was considered significant. Results: Among the 180 patients who were included in study, performance status improvement was noted in significant number of patients (p < 0.001). 38.4% achieved an ECOG (Eastern Cooperative Oncology Group) performance status of 0 post-pre-phase therapy. Febrile neutropenia was observed in 12.8% in the present cohort as compared to the historical non-pre-phase cohort (34%). Conclusions: Pre-phase therapy significantly improves the performance status and diminishes neutropenia rates in DLBCL patients. (© 2022. The Author(s).) |
| References: | Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood. 2006;107(1):265–76. (PMID: 10.1182/blood-2005-06-2508) Pfreundschuh M, Trümper L, Kloess M, Schmits R, Feller AC, Rübe C, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood. 2004;104(3):634–41. (PMID: 10.1182/blood-2003-06-2095) Pfreundschuh M. How I treat elderly patients with diffuse large B-cell lymphoma. Blood. 2010;116(24):5103–10. (PMID: 10.1182/blood-2010-07-259333) Lakshmaiah KC, Asati V, Babu KG, DL, Jacob LA, MCSB, et al. Role of prephase treatment prior to definitive chemotherapy in patients with diffuse large B-cell lymphoma. Eur J Haematol. 2018;100(6):644–8. (PMID: 10.1111/ejh.13068) Cui Y, Li X, Sun Z, Leng C, Young K, Wu X, et al. Safety and efficacy of low-dose pre-phase before conventional-dose chemotherapy for ulcerative gastric diffuse large B-cell lymphoma. Leuk Lymphoma. 2015;56(9):2613–8. (PMID: 10.3109/10428194.2015.1014366) Owens CN, Iannotta A, Gerecitano JF, Matasar MJ, Noy A, Moskowitz CH, et al. Effect of prednisone and rituximab prephase on early toxicity in older DLBCL patients (pts) receiving RCHOP within a NHL specific comprehensive geriatric assessment (CGA) trial. J Clin Oncol. 2015;33(15_suppl):8571. (PMID: 10.1200/jco.2015.33.15_suppl.8571) Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol. 2008;9(2):105–16. (PMID: 10.1016/S1470-2045(08)70002-0) Choi JH, Kim TM, Kim HJ, Koh SA, Mun Y-C, Kang HJ, et al. Multicenter retrospective analysis of clinical characteristics, treatment patterns, and outcomes in very elderly patients with diffuse large B-cell lymphoma: the korean cancer study group LY16-01. Cancer Res Treat Off J Korean Cancer Assoc. 2018;50(2):590–8. |
| فهرسة مساهمة: | Keywords: DLBCL; First cycle effect; Pre-phase |
| المشرفين على المادة: | 4F4X42SYQ6 (Rituximab) 5J49Q6B70F (Vincristine) 80168379AG (Doxorubicin) 8N3DW7272P (Cyclophosphamide) VB0R961HZT (Prednisone) |
| تواريخ الأحداث: | Date Created: 20220508 Date Completed: 20220510 Latest Revision: 20220510 |
| رمز التحديث: | 20221213 |
| DOI: | 10.1186/s43046-022-00116-5 |
| PMID: | 35527285 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 2589-0409 |
|---|---|
| DOI: | 10.1186/s43046-022-00116-5 |